Intracellular islatravir-triphosphate half-life supports extended dosing intervals.
Publication/Presentation Date
9-4-2024
Abstract
Antiretroviral therapy has substantially reduced morbidity, mortality, and disease transmission in people living with HIV. Islatravir is a nucleoside reverse transcriptase translocation inhibitor that inhibits HIV-1 replication by multiple mechanisms of action, and it is in development for the treatment of HIV-1 infection. In preclinical and clinical studies, islatravir had a long half-life (t
Volume
68
Issue
9
First Page
0045824
Last Page
0045824
ISSN
1098-6596
Published In/Presented At
Zang, X., Ankrom, W., Kraft, W. K., Vargo, R., Stoch, S. A., Iwamoto, M., & Matthews, R. P. (2024). Intracellular islatravir-triphosphate half-life supports extended dosing intervals. Antimicrobial agents and chemotherapy, 68(9), e0045824. https://doi.org/10.1128/aac.00458-24
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
39105584
Department(s)
Administration and Leadership
Document Type
Article